PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation.

摘要: // Qiang Ma 1, * , Xiuxiu Wu 2, Jing 3 Huanwen 1 Ying Xiao Lili Wang Zhiyong Liang and Tonghua Liu Department of Pathology, Peking Union Medical College Hospital, Chinese Academy Sciences College, Beijing 100730, P. R. China 2 Respiratory Medicine, Imaging, Huairou University Science, Beijing, 101400, P.R. Authors contributed equally to this work Correspondence to: Liang, email: liangzhiyong1220@yahoo.com Liu, liutonghua_pumc@163.com Keywords: pancreatic cancer, prognosis, PDZK1, PTEN phosphorylation, suppressor Received: July 11, 2017      Accepted: 31, Published: August 24, 2017 ABSTRACT Phosphorylation is a recently established cause phosphatase tensin homolog (PTEN) gene inactivation, which leads defect tumour-suppressor function. In phenomenon has not been reported. Based on database clinical sample analyses, we found that phosphorylation occurs in ductal adenocarcinoma patient tissues cell lines, aimed find method for dephosphorylation. PDZ-containing (PDZK1), tumour-associated protein shares its PDZ-binding sequence with the carboxyl-terminal domain PTEN, was significantly down-regulated cancer as compared adjacent non-tumour tissues. vitro PDZK1 overexpression reversed proliferation migration abilities cells led decreased AKT by interacting wild-type PTEN. addition, transcription factor-activation assay supported enhanced anti-oncogene function regulating activities downstream factors, including p53, NF-κB, FOXO1. vivo nude mice stably over-expressing had lower tumour weights volumes showed xenograft control group. Moreover, low expression strongly correlated advanced stage poor prognosis patients adenocarcinoma. conclusion, our study elucidated role through down-regulating potential novel prognostic marker cancer.